Zilucoplan in pediatric patients with acetylcholine receptor autoantibody positive generalized myasthenia gravis: ziMyG (MG0014) and ziMyG + (MG0015) clinical study designs

MG-ADL and QMG scores over time in patients with generalized myasthenia gravis: Post-hoc analysis of MycarinG and open-label studies

Early responders with zilucoplan: An interim analysis of RAISE-XT in patients with generalized myasthenia gravis

Social determinants of health are associated with suboptimal treatment among individuals with myasthenia gravis

Risk of myasthenia gravis exacerbation and level of healthcare resource utilization by Myasthenia Gravis Activities of Daily Living score

Looking beyond the numbers: Interpreting patient experience of rozanolixizumab in generalized myasthenia gravis from the MycarinG clinical trial

Efficacy of repeated cycles of rozanolixizumab treatment in subgroups of patients with generalized myasthenia gravis: A pooled analysis of a Phase 3 study and two Phase 3 open-label extension studies

Patient-reported outcomes during repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis in the Phase 3 MycarinG and open-label extension studies